September is Fierce. Mark your calendars now.

Arsalan Arif, Publisher
Follow me on twitter and LinkedIn

Labor Day can be traced back to 1872, when a parade was staged in support of the Toronto Typographical Union's strike for a 58-hour work week. FierceMarkets' own typographical union--the editors you've come to depend on for news and analysis every business day--will not publish on Monday, September 5 in observance of U.S. Labor Day. 

It's some well deserved time off. However, the coming weeks won't be slow on the news front. Here are some special dates readers should mark:

  • September 6: Follow @FierceBiotech on twitter for the first Fierce 15 announcements.
  • September 7 - 9: Boston area readers: attend EBD Group's BioPharm America 2011, where you'll meet 9 of the Fierce 15 companies in person. Massachusetts Governor Deval Patrick will attend the Wednesday evening reception. If you're a politico like myself or John Carroll, that's exciting news. In the Boston area next week? Follow us on twitter and let's meet during the event: @arsalanfierce, @johncfierce, @ryanmfierce
  • October 19 (NEW): FierceBiotech holds it's third Fierce Clinical Trials Executive Breakfast in Boston. John Carroll will have more information for readers next week, but I'm thrilled to announce today two of our panelists will be Doug Williams, EVP, R&D at Biogen Idec and Peter Mueller, EVP, Global R&D at Vertex. Save the date now and watch FierceBiotech next week for registration details.

Our goal is to meet a lot of readers next week in Boston. Hope to see you there.

- Arsalan Arif, Group Publisher
Feedback? Ideas? Please email me.

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.